Celsion Corporation
https://celsion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celsion Corporation
Generic ‘Skinny Labels’ Get Reprieve As Court Agrees To Rehear Teva/GSK Case
Federal Circuit panel to reconsider whether Teva induced infringement of GSK Coreg patent despite label carve-out. Biologics and biosimilars could be particularly hurt if ruling stands given FDA’s recent guidance requiring reference to branded product.
Endo’s Par Opts For Authorized Generic As It Debuts Lubiprostone In US
Endo’s Par has introduced the first generic version of Mallinckrodt’s chronic idiopathic constipation medicine Amitiza, realizing the terms of a settlement agreement announced more than six years ago.
Olympus Bolsters Respiratory Portfolio With Up To $340M Buy-Out Of Veran Medical Technologies
Olympus’ acquisition of Veran Medical Technologies will strengthen its respiratory portfolio.
Updated: Reddy's Follows Endo On US Kuvan Launch
Under the terms of a patent-litigation settlement from April 2017, Endo’s Par subsidiary has launched the first US generic versions of BioMarin’s Kuvan (sapropterin) tablet and powder formulations. Rival ANDA sponsor Dr Reddy’s has followed suit on the tablet formulation.
Company Information
- Industry
- Biotechnology
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Egen, Inc.
- Expression Genetics